Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.

BACKGROUND We retrospectively evaluated the prognostic impact of neutrophil-lymphocyte ratio (NLR) as a marker for inflammatory and immune state in men with progressive metastatic castration resistant prostate cancer (mCRPC) following docetaxel. METHODS The SUN-1120 phase III trial comparing prednisone combined with sunitinib (n = 584) or placebo (n = 289) for mCRPC following docetaxel-based chemotherapy was evaluated. The arms were combined for analysis, since no difference was observed in the primary endpoint of overall survival (OS). A logarithmic transformation was applied to non-normal factors. The Kaplan-Meier method was used for OS estimation. To identify an optimal prognostic model for survival, we used a Cox proportional hazards regression method with forward stepwise selection, stratifying for ECOG PS, progression type (prostate specific antigen [PSA] or radiographic) and treatment group. Patients were categorized into risk groups. RESULTS Complete data was evaluable for 784 men. The factors used in the model that remained individually significant for OS in multivariable analysis were: log-lactate dehydrogenase level (LDH) level (HR 2.86 [95% CI = 2.29, 3.56], P < .001), hemoglobin (0.80 [0.74, 0.85], P < .001), > 1 organ involved by metastatic disease (1.49 [1.21, 1.84], P < .001), log-alkaline phosphatase (1.13 [0.99, 1.28], P = .074), log-number of prior cycles of docetaxel (0.84 [0.71, 0.98], P = .031), progression on docetaxel (1.35 [1.00, 1.81], P = .049), log-PSA (1.06 [1.00, 1.12], P = .075) and log-NLR (1.55 [1.32, 1.83], P < .001). NLR increased the c-statistic of the prognostic model from 0.703 to 0.715. CONCLUSION High NLR may be associated with an independent poor prognostic impact in post-docetaxel patients with mCRPC. These data warrant external validation.

[1]  G. Ertas,et al.  Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation , 2013, Journal of the Neurological Sciences.

[2]  P. Ditonno,et al.  Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. , 2013, Future oncology.

[3]  J. Nakashima,et al.  Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. , 2012, The Journal of urology.

[4]  M. Ergelen,et al.  Predictive Value of Elevated Neutrophil to Lymphocyte Ratio in Patients Undergoing Primary Angioplasty for ST-Segment Elevation Myocardial Infarction , 2014, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[5]  D. Morris,et al.  A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. , 2014, Surgical oncology.

[6]  I. Tannock,et al.  Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Xiaoyu Jia,et al.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. , 2009, The Lancet. Oncology.

[9]  M. Carducci,et al.  Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. , 2012, The oncologist.

[10]  G. Pond,et al.  Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy , 2012, BJU international.

[11]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Sung Hoon Kim,et al.  Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment , 2008, Cancer Immunology, Immunotherapy.

[14]  C. Parker,et al.  Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acet , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  I. Tannock,et al.  Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[16]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[17]  E. Jabłońska,et al.  TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. , 2001, Archivum immunologiae et therapiae experimentalis.

[18]  Y. K. Park,et al.  Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer , 2011, Journal of surgical oncology.

[19]  I. Tannock,et al.  A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.

[20]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Horiguchi,et al.  Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. , 2012, Urology.

[22]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Antonarakis,et al.  Association of pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with first‐line docetaxel , 2014, BJU international.

[24]  T. Beer,et al.  C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. , 2012, Urologic oncology.

[25]  P. Hofman,et al.  Predictive clinical outcome of the intratumoral CD66b‐positive neutrophil‐to‐CD8‐positive T‐cell ratio in patients with resectable nonsmall cell lung cancer , 2012, Cancer.

[26]  M. Carducci,et al.  The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. , 2012, European journal of cancer.

[27]  J. Wang,et al.  Activated human neutrophils release hepatocyte growth factor/scatter factor. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  D. Talwar,et al.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. , 2011, European journal of cancer.

[29]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[30]  M. Roh,et al.  Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[31]  S. Doğan,et al.  Neutrophil to lymphocyte ratio: a hopeful marker predicting the disease severity in patients with nonalcoholic fatty liver disease , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[32]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.

[33]  T. Kawano,et al.  Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal Cancer , 2012, World Journal of Surgery.

[34]  P. Kantoff,et al.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  P. Kantoff,et al.  A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  M. Saito,et al.  The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma. , 2013, Urologic oncology.

[37]  N. Marcussen,et al.  Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  F. Saad,et al.  Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Armstrong,et al.  Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. , 2013, Journal of the National Cancer Institute.

[40]  P. Kantoff,et al.  Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. , 2005, Urology.

[41]  N. Pavlakis,et al.  High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy , 2010, Clinical Cancer Research.

[42]  S. El-Sayegh,et al.  Neutrophil-to-Lymphocyte Ratio as a Predictor of Worsening Renal Function in Diabetic Patients (3-Year Follow-Up Study) , 2012, Renal failure.

[43]  J. Wang,et al.  Proinflammatory mediators stimulate neutrophil-directed angiogenesis. , 1999, Archives of surgery.

[44]  M. Lesser,et al.  Neutrophil-Lymphocyte Ratio as a Predictor of Adverse Outcomes of Acute Pancreatitis , 2011, Pancreatology.

[45]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  I. Tannock,et al.  The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. , 2010, European journal of cancer.

[47]  G. Pond,et al.  Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. , 2013, Clinical genitourinary cancer.

[48]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.